PL3368014T3 - Nowe preparaty kannabinoidów - Google Patents

Nowe preparaty kannabinoidów

Info

Publication number
PL3368014T3
PL3368014T3 PL16798004.4T PL16798004T PL3368014T3 PL 3368014 T3 PL3368014 T3 PL 3368014T3 PL 16798004 T PL16798004 T PL 16798004T PL 3368014 T3 PL3368014 T3 PL 3368014T3
Authority
PL
Poland
Prior art keywords
new cannabinoid
cannabinoid preparations
preparations
new
cannabinoid
Prior art date
Application number
PL16798004.4T
Other languages
English (en)
Inventor
Abraham J. Domb
Amnon Hoffman
Dvora IZGELOV
Original Assignee
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd filed Critical Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd
Publication of PL3368014T3 publication Critical patent/PL3368014T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL16798004.4T 2015-10-26 2016-10-26 Nowe preparaty kannabinoidów PL3368014T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562246224P 2015-10-26 2015-10-26
PCT/IL2016/051154 WO2017072762A1 (en) 2015-10-26 2016-10-26 Novel cannabinoid formulations

Publications (1)

Publication Number Publication Date
PL3368014T3 true PL3368014T3 (pl) 2024-03-11

Family

ID=57345998

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16798004.4T PL3368014T3 (pl) 2015-10-26 2016-10-26 Nowe preparaty kannabinoidów

Country Status (8)

Country Link
US (1) US20180325861A1 (pl)
EP (2) EP4279071A3 (pl)
AU (2) AU2016347651A1 (pl)
DK (1) DK3368014T3 (pl)
ES (1) ES2968011T3 (pl)
PL (1) PL3368014T3 (pl)
PT (1) PT3368014T (pl)
WO (1) WO2017072762A1 (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2985332C (en) 2015-05-18 2023-01-03 5071, Inc. Homogenous cannabis compositions and methods of making the same
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
EP3651738B1 (en) * 2017-07-14 2024-04-03 5071, Inc. Cannabinoid compositions and methods of preparation thereof
US20200352901A1 (en) * 2017-09-02 2020-11-12 Scientific Holdings, Llc Tetrahydrocannabinol modulators
EA202090890A1 (ru) * 2017-10-05 2020-09-03 Ресептор Холдингз, Инк. Состав растительного и синтетического каннабиноида быстрого начала действия и пролонгированного действия
WO2020016653A1 (en) * 2018-07-18 2020-01-23 Glatt Gmbh Extended release formulations of cannabinoids
CA3107014A1 (en) * 2018-07-31 2020-02-06 AusCann Group Holdings Ltd Solid self-emulsifying pharmaceutical compositions
IL261132A (en) * 2018-08-13 2018-11-04 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Formulated cannabis oil powder by nanoemulsifycation, methods of producing and uses thereof
WO2020037410A1 (en) * 2018-08-20 2020-02-27 Hexo Operations Inc. Cannabis-infused product with enhanced cannabinoid profile user experience
EP3840854A4 (en) * 2018-08-20 2022-06-29 Bessor Pharma, LLC Novel cannabinoids and cannabinoid acids and their derivatives
US11993563B2 (en) 2018-10-31 2024-05-28 Enantia S.L. Solid compositions of cocrystals of cannabinoids
US20220008348A1 (en) * 2018-11-08 2022-01-13 Michael Golfetto Compound delivery systems and methods of production
WO2020123407A1 (en) * 2018-12-11 2020-06-18 Disruption Labs Inc. Compositions for the delivery of therapeutic agents and methods of use and making thereof
US20200188298A1 (en) 2018-12-14 2020-06-18 NuVessl, Inc. Method For Using Composition With Enhanced Passenger Molecule Loading
WO2020146478A1 (en) * 2019-01-08 2020-07-16 Replennabis LLC Cannabinoid formulations for treating alcohol hangover
WO2020234675A1 (en) * 2019-04-30 2020-11-26 Vialpando, Llc Amorphous cannabinoid composition and processes of manufacture
US11596606B2 (en) 2019-05-30 2023-03-07 Metta Medical Inc Activated cannabinoid controlled release compound tablet and method of forming the same
US12653782B2 (en) 2019-09-12 2026-06-16 Nulixir Inc. Controlled release concentrate and suspensions including the same
EP4072516A1 (en) 2019-12-09 2022-10-19 Nicoventures Trading Limited Oral product comprising a cannabinoid
WO2021163023A1 (en) * 2020-02-10 2021-08-19 TRYAGx Labs Inc. Stable formulations of dronabinol
CN116437909A (zh) * 2020-06-10 2023-07-14 迪斯拉普申实验室公司 用于递送治疗剂的组合物及其使用方法和制备方法
CA3264785A1 (en) * 2022-08-12 2024-02-15 Jazz Pharmaceuticals Research Uk Limited ORAL SOLID DOSAGE FORMS CONTAINING CANNABINOIDS

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7919113B2 (en) 1999-12-30 2011-04-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Dispersible concentrate lipospheres for delivery of active agents
EP1559423A1 (en) * 2004-02-02 2005-08-03 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Medicinal acidic cannabinoids
PT1903866E (pt) 2005-11-07 2016-06-09 Murty Pharmaceuticals Inc Distribuição melhorada de tetra-hidrocanabinol
ES2739194T3 (es) * 2012-01-19 2020-01-29 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Formulación y método para aumentar la biodisponibilidad oral de fármacos
WO2016144376A1 (en) * 2015-03-10 2016-09-15 Nanosphere Health Sciences, Llc Lipid nanoparticle compositions and methods as carriers of cannabinoids in standardized precision-metered dosage forms

Also Published As

Publication number Publication date
AU2022202259B2 (en) 2023-11-09
AU2016347651A1 (en) 2018-05-17
EP4279071A2 (en) 2023-11-22
US20180325861A1 (en) 2018-11-15
AU2022202259A1 (en) 2022-04-21
DK3368014T3 (da) 2024-01-08
PT3368014T (pt) 2024-01-09
EP3368014A1 (en) 2018-09-05
EP4279071A3 (en) 2024-01-17
EP3368014B1 (en) 2023-10-04
ES2968011T3 (es) 2024-05-06
WO2017072762A1 (en) 2017-05-04
CA3003120A1 (en) 2017-05-04

Similar Documents

Publication Publication Date Title
IL289084A (en) Cannabinoid formulations
IL252881A0 (en) Microencapsulated cannabinoid compositions
IL254516B (en) Proteins specific for cd137
DK3283625T3 (da) Nukleasemedieret genomeditering
EP3286361A4 (en) Cancer neoepitopes
EP3119391C0 (en) PROTEIN-BOUND CANNABINOID COMPOSITIONS
DK3550859T3 (da) Hovedtelefonsvirtualisering
DK3331869T3 (da) Muscarinagonister
DK3331528T3 (da) Muskarinagonister
EP3331345A4 (en) Hedge trimmer
DK3277719T3 (da) Polypeptider
EP3316375A4 (en) Redox flow cell
DK3360890T3 (da) Genterapi
DK3305788T3 (da) Janus-kinase-hæmmer
EP3319983C0 (en) TAU LINKING ANTIBODIES
DK3331529T3 (da) Muskarinagonister
EP3290364A4 (en) Conveyor belt wear monitoring system
IL261341B (en) Branch instruction
DK3310450T3 (da) Olie-vand-separator
DK3394281T3 (da) Gærcelle
EP3297518B1 (en) VIDEO LARYNGOSCOPES
DK3270930T3 (da) Præeklampsi
EP3363322A4 (en) Hair extender
EP3325857A4 (en) scraper
DK3292136T3 (da) Penicillin-g-acylaser